The number of drug-induced liver injury (DILI) cases in the U.S. attributable to herbal and dietary supplements and cancer drugs has grown over the past two decades as DILI cases from the leading drug class (antibiotics) declined. (Hepatology)
In a Swedish study, 23% of the general population were found to be at high risk of metabolic dysfunction-associated steatohepatitis (MASH). (Clinical Gastroenterology and Hepatology)
In a phase Ib study of presumed MASH, the investigational oral nonsteroidal selective glucocorticoid receptor modulator miricorilant showed good safety and was associated with reductions in liver fat content. (Hepatology)
Scientists have developed a soft robotic enteroscope that can gently work its way through the small intestine, potentially paving the way for easier tissue biopsy and medication delivery. (Science Robotics)
Why is irritable bowel syndrome so much more common in women? (Washington Post)
Fecal calprotectin testing for patients with lower gastrointestinal symptoms can rule out inflammatory bowel disease (IBD) in the primary care setting, research from the United Kingdom suggested. (Inflammatory Bowel Diseases)
The FDA approved subcutaneous risankizumab (Skyrizi), delivered via an on-body injector, for the induction treatment of moderately to severely active Crohn’s disease in adults, AbbVie announced.
In a randomized trial of short Crohn’s disease strictures, endoscopic stricturotomy topped standard-of-care endoscopic balloon dilation when it came to clinical recurrence rates at 1 year (30% vs 55%). (Clinical Gastroenterology and Hepatology)
What’s the role of fecal microbiota transplant in treating IBD? (Inflammatory Bowel Diseases)
Real-world data on Crohn’s disease patients already exposed to advanced treatments suggested that the interleukin-23 inhibitor risankizumab may perform better in those with ileal involvement compared with the JAK inhibitor upadacitinib (Rinvoq). (Inflammatory Bowel Diseases)
Experts in the American Journal of Gastroenterology reviewed strategies for preventing Clostridioides difficile infections and managing recurrent infections.
With evolving guidelines, watch-and-wait strategies for organ preservation in stages II-III rectal cancer increased from 2.3% in 2015 to 32.9% in 2023. (JAMA Network Open)
Clues to why some early-onset colorectal cancers can be more aggressive. (Nature Medicine)
Patients with gastroesophageal cancers were just as likely to undergo a planned surgical resection whether or not they underwent prehabilitation exercise training following neoadjuvant treatment, a randomized trial found. (JAMA Network Open)
